Abstract: Disclosed herein are heterocyclic compounds that inhibit the binding of menin and MLL or MLL fusion proteins. Also described are specific inhibitors of menin-MLL interaction. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the menin-MLL inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, leukemia and other diseases or conditions dependent on menin-MLL interaction.

Abstract: A balloon guide catheter including a catheter shaft having a main lumen defined therein extending axially therethrough to receive a guidewire therein and an inflation lumen defined axially therein arranged semi-encircling the main lumen. The inflation lumen having an inlet port radially outward from the catheter shaft and an exhaust vent(s) disposed proximate the distal end of the catheter shaft. The exhaust vent(s) being disposed longitudinally through a distal terminating end of the inflation lumen or radially inward in fluid communication with the main lumen. A porous membrane is disposed at the exhaust vent(s) to permit only gas to pass therethrough. Secured about the outer surface proximate the distal end of the catheter shaft and coinciding with the inlet port is a balloon.

Abstract: A system has an outer catheter and an inner aspirating clot retrieval catheter having an expansile distal tip for flow restriction, improved aspiration efficiency, and a large mouth into which a clot or other obstructions can be retrieved. The clot retrieval catheter can have a support tube proximal of the tip. The expansile tip can be a strut framework, and a flexible, low-modulus cover is disposed around at least a portion of the tip strut framework and the proximal support tube. The distal end of the tip can be encapsulated by a low-friction elastomeric lip for atraumatic contact with the walls of a blood vessel. The tip has a collapsed delivery configuration and expands radially into a deployed configuration. The tip strut framework, support tube, and cover can all have characteristics which enhance the deliverability of the clot retrieval catheter to the target.

Abstract: A balloon guide catheter having a sleeved inflation lumen secured with a wire wrap for improved inflation lumen kink protection and a welded balloon construction provides a robust and flexible catheter with an exceptionally large inner lumen relative to its outer profile and enables rapid and reliable balloon inflation and deflation in a highly deliverable and kink resistant catheter. Balloon guide catheters having multiple sleeved inflation lumens and proximal luers for utilizing the multiple inflation lumens are also provided.

Abstract: A computing device includes an appliance status table to store at least one of reliability and performance data for one or more network functions virtualization (NFV) appliances and one or more legacy network appliances. The computing device includes a load controller to configure an Internet Protocol (IP) filter rule to select a packet for which processing of the packet is to be migrated from a selected one of the one or more legacy network appliances to a selected one of the one or more NFV appliances, and to update the appliance status table with received at least one of reliability and performance data for the one or more legacy network appliances and the one or more NFV appliances. The computing device includes a packet distributor to receive the packet, to select one of the one or more NFV appliances based at least in part on the appliance status table, and to send the packet to the selected NFV appliance. Other embodiments are described herein.

Abstract: A stem cell production system provided with a preintroduction cell-feeding solution channel 20 through which a solution containing cells passes, an induction factor-feeding solution mechanism 21 for feeding a pluripotency induction factor to the preintroduction cell-feeding solution channel 20, a factor introduction device 30 connected to the preintroduction cell-feeding solution channel 20 for making cells with induction factor introduced by introducing the pluripotency induction factor into the cells, a cell mass-making device 40 for making multiple cell masses comprising stem cells by culturing the cells with induction factor introduced, and a packaging device 100 for sequentially packaging each of the multiple cell masses.

Abstract: Disclosed herein are heterocyclic compounds that inhibit the binding of menin and MLL or MLL fusion proteins. Also described are specific inhibitors of menin-MLL interaction. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the menin-MLL inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, leukemia and other diseases or conditions dependent on menin-MLL interaction.

Abstract: Disclosed herein are heterocyclic compounds that inhibit the binding of menin and MLL or MLL fusion proteins. Also described are specific irreversible inhibitors of menin-MLL interaction. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the menin-MLL irreversible inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, leukemia and other diseases or conditions dependent on menin-MLL interaction.

Abstract: Disclosed herein are heterocyclic compounds that inhibit the binding of menin and MLL or MLL fusion proteins. Also described are specific irreversible inhibitors of menin-MLL interaction. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the menin-MLL irreversible inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, leukemia and other diseases or conditions dependent on menin-MLL interaction.

Abstract: Disclosed herein are heterocyclic compounds according to formula (I) having the structure that inhibit the binding of menin and MLL or MLL fusion proteins. Also described are specific irreversible inhibitors of menin-HLL interaction. Also disclosed are pharmaceutical compositions that include compounds according to formula (I). Methods of using the menin-HLL irreversible inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, leukemia and other diseases or conditions dependent on menin-MLL interaction.

Abstract: The present disclosure provides a system, apparatus and method for generating randomly aligned fiber beards for evaluation. The system comprises abase and an x-axis frame member couples to and is positioned parallel to the base. A y-axis frame member is couple to and positioned perpendicular to the base. A sample plate is removably coupled to the y-axis frame member and defines one or more holes. A fiber clamp couples to and is movable by the x-axis frame member perpendicularly to the sample plate.

Abstract: Disclosed is a system and method for extraction of information of within sample distribution of fiber quality from high-volume instrument (HVI) fibrogram to better predict yarn quality than the standard HVI output. The present invention allows for information on fiber quality to be obtained while avoiding testing samples with more expensive techniques. The disclosed system and method extracts HVI data for collecting a respective set of initial fibrograms from a set of fiber samples and representing them as a distance matrix to form a matrix of transformed fibrogram data, said matrix of transformed fibrogram data comprising a vector of scores to represent each sample and thereafter explaining variation in yarn quality by extracting all of the information available from the fibrogram.

Abstract: A method watermarks speech data by using a generator to generate speech data including a watermark. The generator is trained to generate the speech data including the watermark. The training process generates first speech from the generator. The first speech data is configured to represent speech. The first speech data includes a candidate watermark. The training also produces an inconsistency message as a function of at least one difference between the first speech data and at least authentic speech data. The training further includes transforming the first speech data, including the candidate watermark, using a watermark robustness module to produce transformed speech data including a transformed candidate watermark. The transformed speech data includes a transformed candidate watermark. The training further produces a watermark-detectability message, using a watermark detection machine learning system, relating to one or more desirable watermark features of the transformed candidate watermark.

Abstract: A stem cell production system provided with a preintroduction cell-feeding solution channel 20 through which a solution containing cells passes, an induction factor-feeding solution mechanism 21 for feeding a pluripotency induction factor to the preintroduction cell-feeding solution channel 20, a factor introduction device 30 connected to the preintroduction cell-feeding solution channel 20 for making cells with induction factor introduced by introducing the pluripotency induction factor into the cells, a cell mass-making device 40 for making multiple cell masses comprising stem cells by culturing the cells with induction factor introduced, and a packaging device 100 for sequentially packaging each of the multiple cell masses.

Abstract: A stem cell production system provided with a preintroduction cell-feeding solution channel 20 through which a solution containing cells passes, an induction factor-feeding solution mechanism 21 for feeding a pluripotency induction factor to the preintroduction cell-feeding solution channel 20, a factor introduction device 30 connected to the preintroduction cell-feeding solution channel 20 for making cells with induction factor introduced by introducing the pluripotency induction factor into the cells, a cell mass-making device 40 for making multiple cell masses comprising stem cells by culturing the cells with induction factor introduced, and a packaging device 100 for sequentially packaging each of the multiple cell masses.

Abstract: Systems and methods for reconstructing an image of a subject or object based on a plurality of measured signals representing the subject or object obtained by an imaging device are disclosed. The systems and methods reconstruct the image of the subject or object by performing an iterative reconstruction method to produce a plurality of intermediate images and the image of the subject, and transforming at least one selected intermediate image from the plurality of intermediate images using a quasi-projection operator. The quasi-projection operator includes a deep-learning model configured to map the at least one selected intermediate image to at least one regularized intermediate image. In addition, systems and methods for training the deep-learning model using a training data set that includes a plurality of training images and a plurality of corresponding training object images is disclosed.

Abstract: Disclosed herein are heterocyclic compounds that inhibit the binding of menin and MLL or MLL fusion proteins. Also described are specific irreversible inhibitors of menin-MLL interaction. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the menin-MLL irreversible inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, leukemia and other diseases or conditions dependent on menin-MLL interaction.

Abstract: The present invention provides a stem cell manufacturing system comprising: a pre-transfer cell solution sending channel 20 through which a solution containing cells flows; an inducer solution sending mechanism 21 which sends a pluripotency inducer into the pre-transfer cell solution sending channel 20; an inducer transfer apparatus 30 which is connected to the pre-transfer cell solution sending channel 20 and transfers the pluripotency inducer into the cells to produce cells harboring the inducer; a cell cluster production apparatus 40 which cultures the cells harboring the inducer to produce a plurality of cell clusters consisting of stem cells; and a packaging apparatus 100 which sequentially packages the plurality of cell clusters.

Abstract: The present invention provides a stem cell manufacturing system comprising: a sending channel (20) through which a solution containing cells flows; an apparatus (30) which is connected to the sending channel (20) and transfers a pluripotency inducer into the cells to produce cells harboring the inducer; and an apparatus (40) which cultures the cells harboring the inducer to produce cell clusters consisting of stem cells.

Abstract: Disclosed herein are heterocyclic compounds that inhibit the binding of menin and MLL or MLL fusion proteins. Also described are specific inhibitors of menin-MLL interaction. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the menin-MLL inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, leukemia and other diseases or conditions dependent on menin-MLL interaction.